Emmes Group Appointed Rama Kondru as CEO
The clinical research firm tapped the former Veridix CEO to lead its pivot toward AI-driven clinical trials.
Updated on Sept. 21, 2026 in People
Live Poll
Do you believe new executive leadership usually leads to better outcomes for a company's stakeholders?
The Emmes Group Board of Directors appointed Rama Kondru as CEO to spearhead the company's efforts in integrating AI and technology into clinical trial design. Kondru, who joined the organization in 2024, brings 25 years of experience across pharmaceuticals, healthcare technology, data science, and academia.
Why it matters
The leadership change signals a strategic push by the firm to modernize clinical trial conduct through advanced data platforms. This move is intended to leverage Kondru's background in scaling technology to transform how clinical research is designed and executed.
New CEO Rama Kondru brings 25 years of experience in pharmaceuticals and healthcare technology to the role. The firm is now tasked with managing the integration of AI platforms into existing clinical research frameworks.
The players
Rama Kondru
The new CEO of the Emmes Group who previously led Veridix and served as Co-CEO of Medidata Solutions.
The Emmes Group
A clinical research organization focused on conducting and designing clinical trials for the healthcare industry.
The details
The board selected Kondru specifically for his history of scaling technology platforms and his background in global operations. The company plans to operationalize this transition by merging its historical clinical expertise with new data science capabilities to improve trial design efficiency. This appointment follows Kondru's tenure as CEO of Veridix and his prior roles as Co-CEO of Medidata Solutions and CIO for Janssen Americas.
Timeline
• Rama Kondru joined the Emmes Group in 2024.
• The appointment was officially announced on September 21, 2026.
Market Landscape
This move tracks with the clinical research sector's industry-wide adoption of AI-driven trial protocols. The appointment positions the firm to compete more aggressively with tech-heavy research platforms that have recently gained significant market share.
Owners and operators in the clinical technology space should monitor the firm's upcoming pilot programs for shifts in trial design standards. The integration of AI and data science at this level will likely reset competitive benchmarks for trial timelines and data management costs.
The takeaway
The appointment underscores the growing necessity for clinical firms to pair traditional subject-matter expertise with technology-scaling experience. Operators should review their own organizations' readiness to integrate data science platforms into core service offerings.
Further reading
For more on shifts in the industry executive landscape, visit People.
Source note: This article includes information reported by PMLive.
Live Poll
Do you believe new executive leadership usually leads to better outcomes for a company's stakeholders?
